The list price of Mavenclad is around £2,050 per 10mg tablet, although, Merck is providing it to the NHS in England at a ...

The negotiated prices would then take effect in January of 2028, Merck said in a recent annual SEC filing (PDF ... has already had two drugs picked for the yearly list of drugs subject ...

Biotech Halozyme Therapeutics believes the new version of Merck's blockbuster cancer drug Keytruda infringes on its patents, the Wall Street Journal reported on Wednesday (March 5, 2025), citing ...

Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a new version of its crucial cancer drug Keytruda. Enzyme Dispute ...

The approvals are backed by Merck’s (NYSE:MRK) LITESPARK-004 and LITESPARK-005 trials, respectively. An expert panel of the EU drug regulator, the European Medicines Agency, endorsed the ...

Europe Approves Merck's Cancer Drug For Two Indications On Tuesday, the European Commission (EC) conditionally approved Merck & Co Inc’s (NYSE:MRK) Welireg (belzutifan), an oral hypoxia ...

March 5 (Reuters) - Merck's (MRK.N), opens new tab injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics (HALO.O ...

A dispute over a microscopic enzyme is threatening Merck & Co. plans to sell a new version of Keytruda, the cancer drug that generates nearly half of the company’s sales. Merck has been tweaking ...

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) therapies after its drug candidate pimicotinib cleared a phase 3 trial.

We recently compiled a list of the 13 Cheap High Dividend Stocks To Invest In Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other cheap ...

DURHAM, N.C. (WTVD) -- Drugmaker Merck announced Tuesday the opening of a new facility in North Durham. The $1 billion plant will manufacture the HPV vaccines Gardasil and Gardasil 9, while the ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg. Gilead had the right to ...